...NASDAQ:AMGN) (see BioCentury Extra, Jan. 19) . Pfizer also will gain Anacor's onychomycosis drug Kerydintavaborole... ...in the U.S. In 2015, Anacor recorded $60.5 million in gross profit sharing revenue from Kerydin...
...PTAB) of the U.S. Patent and Trademark Office challenging patents covering Anacor’s onychomycosis drug Kerydintavaborole... ...and two petitions against U.S. Patent No. 7,767,657. The ‘657 patent claims topical formulations of Kerydin...
...Rosacea drug Oracea doxycycline from Galderma S.A. (Lausanne, Switzerland) and onychomycosis drug Kerydintavaborole from Anacor... ...and two petitions against U.S. Patent No. 7,767,657. The '657 patent claims topical formulations of Kerydin... ...treat onychomycosis and related diseases. The '621 patent claims methods of treating fungal infections with Kerydin...
...approves G-Lasta pegfilgrastim to treat chemotherapy-induced febrile neutropenia Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) FDA approves Kerydintavaborole...
...said the Sandoz Inc. generics unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) launched Kerydintavaborole... ...Sandoz has exclusive, U.S. commercialization rights under a July deal. Sandoz said it would distribute Kerydin...
...Anacor granted Novartis’ Sandoz Inc. generics unit exclusive rights in the U.S. to commercialize Kerydintavaborole... ...in 2016 totaling $45 million. Anacor also has the option to repurchase all rights to Kerydin... ...from the launch of the drug or Dec. 31, 2017. Anacor will supply Sandoz with Kerydin...
